Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor (Q33183732)

23 July 2017

title

Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor (English)

1 reference

23 July 2017

1

Daniel Guay

1 reference

23 July 2017

Pierre Hamel

2

1 reference

23 July 2017

Marc Blouin

3

1 reference

23 July 2017

Christine Brideau

4

1 reference

23 July 2017

Chi Chung Chan

5

1 reference

23 July 2017

Nathalie Chauret

6

1 reference

23 July 2017

Yves Ducharme

7

1 reference

23 July 2017

Zheng Huang

8

1 reference

23 July 2017

Mario Girard

9

1 reference

23 July 2017

Tom R Jones

10

1 reference

23 July 2017

France Laliberté

11

1 reference

23 July 2017

Paul Masson

12

1 reference

23 July 2017

Malia McAuliffe

13

1 reference

23 July 2017

Hanna Piechuta

14

1 reference

23 July 2017

José Silva

15

1 reference

23 July 2017

Robert N Young

16

1 reference

23 July 2017

Yves Girard

17

1 reference

23 July 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Bioorganic & Medicinal Chemistry Letters

23 July 2017

published in

1 reference

23 July 2017

volume

12

1 reference

23 July 2017

issue

11

1 reference

23 July 2017

page(s)

1457-1461

1 reference

Genomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domains

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Therapeutic strategies for allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

The next generation of PDE4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

House dust mite-induced airway changes in hu-SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Expired nitric oxide and airway obstruction in asthma patients with an acute exacerbation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

Conformational difference between PDE4 apoenzyme and holoenzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900190-7

7 January 2021

10.1016/S0960-894X(02)00190-7

Identifiers

DOI

1 reference

23 July 2017

1 reference